Powered by

BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy

Mar 01, 2017 - PR Newswire

 Amgen (NASDAQ:AMGN) today announced theNew England Journal of Medicinepublished results from the Phase 3 TOWER study evaluating the efficacy of BLINCYTO® (blinatumomab) versus standard of care (SOC) chemotherapy in high-risk adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), one of the most aggressive B-cell malignancies. Results from the analysis showed that median overall survival (OS) was 7.7 months (95 per...